Medical Oncology

, 34:170 | Cite as

Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer

Review Article

Abstract

Bladder cancer is the most common malignancy involving the genitourinary system (Siegel et al. in CA Cancer J Clin, 66:7–30, 2016). In the USA, it is the fifth most common cancer and approximately 79,000 new cases will be diagnosed in 2017 (Siegel et al. in CA Cancer J Clin, 66:7–30, 2016). The mortality from bladder cancer is approximately 17,000 deaths each year (Siegel et al. in CA Cancer J Clin, 66:7–30, 2016). The incidence rate for bladder cancer is higher in men compared to women. Risk factors are predominantly related to tobacco smoking, although infection with Schistosoma haematobium is another risk factor in selected populations (Antoni et al. in Eur Urol, 71:96–108, 2017). Cisplatin-based systemic chemotherapy regimens remain the standard of care in both the neoadjuvant and metastatic setting for muscle-invasive bladder cancer (Gupta et al. in Cancer, 9(15):1–14, 2017; Von der Maase et al. in J Clin Oncol, 23:4602–4608, 2005; De Santis et al. in J Clin Oncol, 30:191–199, 2012; Bellmunt et al. in J Clin Oncol, 27: 4454–4461, 2009). There is an estimated overall survival of 9–15 months in metastatic bladder cancer in those who receive the standard of care platinum-based chemotherapy (Von der Maase et al. in J Clin Oncol, 23:4602–4608, 2005; De Santis et al. in J Clin Oncol, 30:191–199, 2012). The median survival, however, is significantly reduced after relapse in patient treated with platinum chemotherapy to less than 7 months (Bellmunt et al. in J Clin Oncol, 27: 4454–4461, 2009). Thus, this approach is preferred for patients who can tolerate this treatment as first-line chemotherapy (Gupta et al. in Cancer, 9(15):1–14, 2017). Until recently, there were few treatment options for those patients with poor performance status who are ineligible to receive cisplatin including renal insufficiency and multiple comorbidities or had disease progression after receiving platinum-based chemotherapy (Gupta et al. in Cancer, 9(15):1–14, 2017). With further understanding of tumor immune evasion, systemic immunotherapy which utilizes the patient’s own immune system directly to eradicate and target neoplastic cells, has now been approved for urothelial bladder cancer. Monoclonal antibodies that target programmed cell death protein 1 (PD-1), including Nivolumab and Pembrolizumab, and its ligand, PD-L1, including Atezolizumab, Durvalumab, Avelumab, have all been investigated and approved in the setting of metastatic refractory urothelial cancer (Gupta et al. in Cancer, 9(15):1–14, 2017; Von der Maase et al. in J Clin Oncol, 23:4602–4608, 2005; Zilchi et al. in BioMed Res Int, 2017, 2017, doi: 10.1155/2017/5618174). Atezolizumab and Pembrolizumab have also been approved as first-line therapy in the setting of cisplatin-ineligible metastatic bladder cancer (Gupta et al. in Cancer, 9(15):1–14, 2017; Zilchi et al. in BioMed Res Int, 2017, 2017, doi: 10.1155/2017/5618174). Those that target cytotoxic T-lymphocyte-associated protein 4, including Ipilimumab and Tremelimumab, have also been investigated and further studies are being performed (Gupta et al. in Cancer, 9(15):1–14, 2017; Zilchi et al. in BioMed Res Int, 2017, 2017, doi: 10.1155/2017/5618174). This review outlines the systemic immunotherapies that have been approved or are currently being investigated.

Keywords

Urothelial bladder cancer Immune therapy Checkpoint inhibitors 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

No animal or human were involved in this study.

References

  1. 1.
    Finn O. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(Supplement 8):viii6–9. doi: 10.1093/annonc/mds256.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rosenberg J, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Massard C, Gordon M, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119–25.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Heery C, O’Sullivan-Coyne G, Madan R, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587–98.CrossRefPubMedGoogle Scholar
  6. 6.
    Apolo A, Infante J, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35(19):2117–24.CrossRefPubMedGoogle Scholar
  7. 7.
    Patel M, Ellerton J, Infante J, et al. Avelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN solid tumor trial. J Clin Oncol. 2017; 35(supplement 6S), abstract 330.Google Scholar
  8. 8.
    Sharma P, Callahan M, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (Check-Mate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (Check-Mate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22.CrossRefPubMedGoogle Scholar
  10. 10.
    Plimack E, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Balar A, Castellano D, O’Donnell P, et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from the total KEYNOTE-052 study population. J Clin Oncol. 2017; 35(supplement 6S), abstract 284.Google Scholar
  12. 12.
    Bellmunt J, de Wit R, Vaughn D, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.CrossRefPubMedGoogle Scholar
  13. 13.
    Carthon B, Wolchok J, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16(10):2861–71.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Prescott S, Jackson A, Hawkyard S, et al. Mechanisms of action of intravesical bacille Calmette–Guérin: local immune mechanisms. Clin Infect Dis. 2000;31(Suppl 3):S91.CrossRefPubMedGoogle Scholar
  15. 15.
    Grossman H, Natale R, Tangen C, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.CrossRefPubMedGoogle Scholar
  16. 16.
    Sternberg C, de Mulder P, Schornagel J, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638–46.CrossRefPubMedGoogle Scholar
  17. 17.
    Dash A, Pettus J, Herr H, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113:2471–7.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48:189–99 (discussion 199-201).CrossRefGoogle Scholar
  19. 19.
    Siegel R, Miller K, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108.CrossRefPubMedGoogle Scholar
  21. 21.
    Gupta S, Gill D, Poole A, Agarwal N. Systemic immunotherapy for urothelial cancer: current trends and future direction. Cancer. 2017;9(15):1–14.Google Scholar
  22. 22.
    Von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.CrossRefPubMedGoogle Scholar
  23. 23.
    De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454–61.CrossRefPubMedGoogle Scholar
  25. 25.
    Zilchi C, Tucci M, Leone G, et al. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. BioMed Res Int. 2017; 2017, Article ID 5618174. doi: 10.1155/2017/5618174.

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of Hematology/OncologyJoan C. Edwards School of Medicine Marshall UniversityHuntingtonUSA
  2. 2.Department of Internal MedicineJoan C. Edwards School of Medicine Marshall UniversityHuntingtonUSA
  3. 3.Division of Hematology, Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Joan C. Edwards School of MedicineMarshall UniversityHuntingtonUSA

Personalised recommendations